Parexel to be acquired by PE in $5bn deal

By Melissa Fassbender contact

- Last updated on GMT

Parexel has entered an agreement to be acquired by Pamplona Capital Management. (Image: iStock/pichet_w)
Parexel has entered an agreement to be acquired by Pamplona Capital Management. (Image: iStock/pichet_w)
Parexel International Corporation has signed a definite agreement to be acquired by the private equity firm Pamplona Capital Management, LLP.

Under the agreement, announced this morning, Pamplona will acquire all outstanding shares of the contract research organization (CRO) for $88.10 per share in cash.

The transaction, which is valued at approximately $5.0bn, is expected to close early in the fourth quarter of 2017.

Today’s announcement is the culmination of a comprehensive review of the opportunities available to the Company, including interest solicited and received from multiple parties with the assistance of independent financial and legal advisors,​” Josef von Rickenbach, Chairman and CEO of Parexel commented in the release.

Pamplona has previously invested in nThrive, Formativ Health, Brighton Health Group, Alvogen, Spreemo, PatientCo, and Intralign.

The deal comes on the heels of several private equity investments​ in the contract research and manufacturing industry, including the recent purchase of AMRI by The Carlyle Group.

Parexel is not providing any additional comment at this time.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers